{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:17:19Z","timestamp":1794003439663,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is an upper airways disease predominantly characterized by type 2 (T2) inflammation, leading to reduced quality of life and patient\/healthcare burden. Many patients remain underdiagnosed for T2 inflammation in clinical practice as it is not often defined\/considered, resulting in inadequate disease management. This research aimed to develop and evaluate a patient management plan (PMP) to be used by healthcare professionals (HCPs) in clinical practice to improve the management and standardization of management of patients with CRSwNP in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A working group of six otorhinolaryngology (ORL) specialists and one patient advocacy group (PAG) representative, who form part of the European CRSwNP Alliance, developed the PMP. Two online surveys were disseminated to ORLs\/PAGs and national CRSwNP Alliance members in December 2024 and January 2025, respectively, to evaluate the design and potential utility of the PMP in clinical practice across Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Survey 1 respondents agreed that key themes in the initial PMP (patient symptoms, management of comorbidities, agreed treatment goals, follow-up management) were likely to be effective in improving patient management. Respondents across both surveys suggested that the PMP would improve shared decision-making, follow-up, adherence, and increase understanding of CRSwNP as a chronic inflammatory condition. They agreed that the PMP could standardize the management of CRSwNP across Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PMP could support patient\u2013HCP education and communication, supplement management guidance, enhance shared decision-making, and ensure a timely, personalized, long-term treatment and management approach, including follow-up, for patients with CRSwNP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00405-025-09763-5","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T19:55:33Z","timestamp":1765396533000},"page":"249-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes"],"prefix":"10.1007","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-4073","authenticated-orcid":false,"given":"Adam M.","family":"Chaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Heirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Verillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Hox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"9763_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC (2016) Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 4:565\u2013572. https:\/\/doi.org\/10.1016\/j.jaip.2016.04.012","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9763_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4193\/rhin23.341","volume":"62","author":"J Mullol","year":"2024","unstructured":"Mullol J, Sastre J, Dominguez-Ortega J et al (2024) Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain. Rhinology 62:421\u2013431. https:\/\/doi.org\/10.4193\/rhin23.341","journal-title":"Rhinology"},{"key":"9763_CR3","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1111\/all.15301","volume":"77","author":"A Starry","year":"2022","unstructured":"Starry A, Hardtstock F, Wilke T et al (2022) Epidemiology and treatment of patients with chronic rhinosinusitis with nasal polyps in Germany-a claims data study. Allergy 77:2725\u20132736. https:\/\/doi.org\/10.1111\/all.15301","journal-title":"Allergy"},{"key":"9763_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/all.12983","volume":"72","author":"J van der Veen","year":"2017","unstructured":"van der Veen J, Seys SF, Timmermans M et al (2017) Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 72:282\u2013290. https:\/\/doi.org\/10.1111\/all.12983","journal-title":"Allergy"},{"key":"9763_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081251","author":"E De Corso","year":"2022","unstructured":"De Corso E, Baroni S, Settimi S et al (2022) Sinonasal biomarkers defining type 2-high and type 2-low inflammation in chronic rhinosinusitis with nasal polyps. J Pers Med 1251. https:\/\/doi.org\/10.3390\/jpm12081251","journal-title":"J Pers Med"},{"key":"9763_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 9:1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9763_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/alr.22994","volume":"12","author":"P Gevaert","year":"2022","unstructured":"Gevaert P, Han JK, Smith SG et al (2022) The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 12:1413\u20131423. https:\/\/doi.org\/10.1002\/alr.22994","journal-title":"Int Forum Allergy Rhinol"},{"key":"9763_CR8","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.amjoto.2019.102286","volume":"41","author":"D Rosati","year":"2020","unstructured":"Rosati D, Rosato C, Pagliuca G et al (2020) Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol 41:102286. https:\/\/doi.org\/10.1016\/j.amjoto.2019.102286","journal-title":"Am J Otolaryngol"},{"key":"9763_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1159\/000530193","volume":"184","author":"CL Guo","year":"2023","unstructured":"Guo CL, Lu RY, Wang CS et al (2023) Identification of inflammatory endotypes by clinical characteristics and nasal secretion biomarkers in chronic rhinosinusitis with nasal polyps. Int Arch Allergy Immunol 184:955\u2013965. https:\/\/doi.org\/10.1159\/000530193","journal-title":"Int Arch Allergy Immunol"},{"key":"9763_CR10","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","volume":"15","author":"C Bachert","year":"2024","unstructured":"Bachert C, Hicks A, Gane S et al (2024) The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol 15:1356298. https:\/\/doi.org\/10.3389\/fimmu.2024.1356298","journal-title":"Front Immunol"},{"key":"9763_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58:1\u2013464. https:\/\/doi.org\/10.4193\/rhin20.600","journal-title":"Rhinology"},{"key":"9763_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13223-024-00879-7","volume":"20","author":"J Hwee","year":"2024","unstructured":"Hwee J, Lee L, Small M et al (2024) The chronic rhinosinusitis with nasal polyp patient journey in the United States and Europe. Allergy Asthma Clin Immunol 20:17. https:\/\/doi.org\/10.1186\/s13223-024-00879-7","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9763_CR13","doi-asserted-by":"publisher","first-page":"e022644","DOI":"10.1136\/bmjopen-2018-022644","volume":"9","author":"J Vennik","year":"2019","unstructured":"Vennik J, Eyles C, Thomas M et al (2019) Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care. BMJ Open 9:e022644. https:\/\/doi.org\/10.1136\/bmjopen-2018-022644","journal-title":"BMJ Open"},{"key":"9763_CR14","doi-asserted-by":"publisher","first-page":"1137907","DOI":"10.3389\/falgy.2023.1137907","volume":"4","author":"SP Ramkumar","year":"2023","unstructured":"Ramkumar SP, Lal D, Miglani A (2023) Considerations for shared decision-making in treatment of chronic rhinosinusitis with nasal polyps. Front Allergy 4:1137907. https:\/\/doi.org\/10.3389\/falgy.2023.1137907","journal-title":"Front Allergy"},{"key":"9763_CR15","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74:2312\u20132319. https:\/\/doi.org\/10.1111\/all.13875","journal-title":"Allergy"},{"key":"9763_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11882-023-01118-6","volume":"24","author":"M Caminati","year":"2024","unstructured":"Caminati M, De Corso E, Ottaviano G et al (2024) Remission in type 2 inflammatory diseases: current evidence, unmet needs, and suggestions for defining remission in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep 24:11\u201323. https:\/\/doi.org\/10.1007\/s11882-023-01118-6","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1434\u20131453","key":"9763_CR17","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.jaip.2022.03.002","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA (2022) Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract 10(1434\u20131453):e9. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.002","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9763_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi RR, Kingdom TT, Smith TL et al (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 11:213\u2013739. https:\/\/doi.org\/10.1002\/alr.22741","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1069\u20131076","key":"9763_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.02.020","volume":"125","author":"T Van Zele","year":"2010","unstructured":"Van Zele T, Gevaert P, Holtappels G et al (2010) Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol 125(1069\u20131076):e4. https:\/\/doi.org\/10.1016\/j.jaci.2010.02.020","journal-title":"J Allergy Clin Immunol"},{"key":"9763_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/jaa.s290424","volume":"14","author":"C Bachert","year":"2021","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, Khan AH (2021) Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 14:127\u2013134. https:\/\/doi.org\/10.2147\/jaa.s290424","journal-title":"J Asthma Allergy"},{"key":"9763_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox V, Lourijsen E, Jordens A et al (2020) Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 10:1. https:\/\/doi.org\/10.1186\/s13601-019-0303-6","journal-title":"Clin Transl Allergy"},{"key":"9763_CR22","unstructured":"(2023) Dupixent product monograph including patient medication information. https:\/\/pdf.hres.ca\/dpd_pm\/00070465.PDF. Accessed 17\/12\/2024"},{"key":"9763_CR23","unstructured":"(2022) Nucala product monograph including patient medication information. https:\/\/pdf.hres.ca\/dpd_pm\/00067402.PDF. Accessed 17\/12\/2024"},{"key":"9763_CR24","unstructured":"(2023) Xolair product monograph including patient medication information. https:\/\/pdf.hres.ca\/dpd_pm\/00070876.PDF. Accessed 17\/12\/2024"},{"key":"9763_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V et al (2023) EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61:194\u2013202. https:\/\/doi.org\/10.4193\/rhin22.489","journal-title":"Rhinology"},{"key":"9763_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/rhin23.415","volume":"62","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens WJ, De Corso E, Backer V et al (2024) EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology 62:287\u2013298. https:\/\/doi.org\/10.4193\/rhin23.415","journal-title":"Rhinology"},{"key":"9763_CR27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/jaa.s258438","volume":"14","author":"JC Morse","year":"2021","unstructured":"Morse JC, Miller C, Senior B (2021) Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J Asthma Allergy 14:873\u2013882. https:\/\/doi.org\/10.2147\/jaa.s258438","journal-title":"J Asthma Allergy"},{"key":"9763_CR28","doi-asserted-by":"publisher","first-page":"100895","DOI":"10.1016\/j.waojou.2024.100895","volume":"17","author":"D Bagnasco","year":"2024","unstructured":"Bagnasco D, Brussino L, Biagini C et al (2024) Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): results from a survey among allergists and clinical immunologists of the North-West and Center Italy inter-regional sections of SIAAIC and otorhinolaryngologists of national IAR. World Allergy Organ J 17:100895. https:\/\/doi.org\/10.1016\/j.waojou.2024.100895","journal-title":"World Allergy Organ J"},{"key":"9763_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/jaa.s447093","volume":"17","author":"S Toppila-Salmi","year":"2024","unstructured":"Toppila-Salmi S, Bjermer L, Cardell LO et al (2024) Multi-disciplinary expert perspective on the management of type 2 inflammation-driven severe CRSwNP: a brief overview of pathophysiology and recent clinical insights. J Asthma Allergy 17:431\u2013439. https:\/\/doi.org\/10.2147\/jaa.s447093","journal-title":"J Asthma Allergy"},{"key":"9763_CR30","doi-asserted-by":"publisher","first-page":"741788","DOI":"10.3389\/falgy.2021.741788","volume":"2","author":"S Vlaminck","year":"2021","unstructured":"Vlaminck S, Acke F, Scadding GK, Lambrecht BN, Gevaert P (2021) Pathophysiological and clinical aspects of chronic rhinosinusitis: current concepts. Front Allergy 2:741788. https:\/\/doi.org\/10.3389\/falgy.2021.741788","journal-title":"Front Allergy"},{"key":"9763_CR31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2024","unstructured":"Hellings PW, Alobid I, Anselmo-Lima WT et al (2024) EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy 79:1123\u20131133. https:\/\/doi.org\/10.1111\/all.15982","journal-title":"Allergy"},{"issue":"1532\u20131549","key":"9763_CR32","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaip.2020.02.023","volume":"8","author":"R Naclerio","year":"2020","unstructured":"Naclerio R, Baroody F, Bachert C et al (2020) Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a national institute of allergy and infectious diseases workshop. J Allergy Clin Immunol Pract 8(1532\u20131549):e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9763_CR33","doi-asserted-by":"publisher","first-page":"1447747","DOI":"10.3389\/fpubh.2024.1447747","volume":"12","author":"Z Shi","year":"2024","unstructured":"Shi Z, Du X, Li J et al (2024) Factors influencing digital health literacy among older adults: a scoping review. Front Public Health 12:1447747. https:\/\/doi.org\/10.3389\/fpubh.2024.1447747","journal-title":"Front Public Health"},{"key":"9763_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18176\/jiaci.0910","volume":"33","author":"I Alobid","year":"2023","unstructured":"Alobid I, Colas C, Castillo JA et al (2023) Spanish consensus on the management of chronic rhinosinusitis with nasal polyps (POLIposis NAsal\/POLINA 2.0). J Investig Allergol Clin Immunol 33:317\u2013331. https:\/\/doi.org\/10.18176\/jiaci.0910","journal-title":"J Investig Allergol Clin Immunol"},{"key":"9763_CR35","doi-asserted-by":"publisher","first-page":"e1277","DOI":"10.1002\/lio2.1277","volume":"9","author":"S Alsaleh","year":"2024","unstructured":"Alsaleh S, Kamal N, Hopkins C et al (2024) Assessment of chronic rhinosinusitis with nasal polyps: development of the nasal polyp patient assessment scoring sheet tool. Laryngoscope Investig Otolaryngol 9:e1277. https:\/\/doi.org\/10.1002\/lio2.1277","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"9763_CR36","unstructured":"Chronic rhinosinusitis patient portal. https:\/\/www.euforea.eu\/patient-portal\/crs-welcome\/. Accessed 02\/09\/2025"},{"key":"9763_CR37","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/clt2.70010","volume":"15","author":"O Pfaar","year":"2025","unstructured":"Pfaar O, Peters AT, Taille C et al (2025) Chronic rhinosinusitis with nasal polyps: key considerations in the multidisciplinary team approach. Clin Transl Allergy 15:e70010. https:\/\/doi.org\/10.1002\/clt2.70010","journal-title":"Clin Transl Allergy"},{"key":"9763_CR38","doi-asserted-by":"publisher","first-page":"e21389","DOI":"10.1097\/md.0000000000021389","volume":"99","author":"V Coronado-Vazquez","year":"2020","unstructured":"Coronado-Vazquez V, Canet-Fajas C, Delgado-Marroquin MT et al (2020) Interventions to facilitate shared decision-making using decision aids with patients in primary health care: a systematic review. Medicine (Baltimore) 99:e21389. https:\/\/doi.org\/10.1097\/md.0000000000021389","journal-title":"Medicine (Baltimore)"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09763-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:16:10Z","timestamp":1770966970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["9763"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09763-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was non-clinical, non-interventional market research, it was exempt from Clinical Research Ethics Committee or Independent Review Board approval, per the European Pharmaceutical Market Research Association 2024 code of conduct.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"AMC reports personal fees including grants, speaker honoraria, consultancy or advisory fees, and\/or research support and other from ALK-Abell\u00f3, AstraZeneca, Bencard Allergie, European Institute of Education and Technology (EIT Health), Federal Ministry of Education and Research (Germany), GSK, Hippo Dx, LETI, Novartis, Regeneron, Roche, Sanofi, Technical University of Munich from Allergopharma, Thermo Fisher Scientific, and Zeller.EC reports personal fees including honoraria, consulting, and lecture fees from AstraZeneca, GSK, Neopharma Gentili, NOOS, and Sanofi.PWH reports personal fees including unrestricted research grants and lecture honoraria from ALK, GSK, Novartis, Regeneron, Sanofi, and Viatris.NH is employed by, and holds financial equities, in GSK.BV reports personal fees including honoraria, consulting, and lecture fees from Amplifon, Collin, GSK, Medtronic, Mylan, and Sanofi.VH reports consultancy and speaker fees from AstraZeneca, ALK, Celltrion, GSK, and Sanofi.CJ has no conflicts of interest to declare.JM is or has been a member of national and international scientific advisory boards, received fees for lectures and grants for research projects or clinical trials from Almirall, AstraZeneca, GSK, LETI, Lilly, Menarini, MSD, NOUCOR\/Uriach Group, Novartis, OptiNose, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB Pharma, and Viatris\/MEDA Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}